Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof

1. A compound having structural formula I:

or a substantially pure enantiomer thereof, or a pharmaceutically acceptable salt of either of the foregoing, wherein:

R 1 is selected from —Cl, —CH 3 , —CH 2 CH 3 , —CH 2 CH 2 CH 3 , —NH(CH 3 ), —OCH 3 , —OCHF 2 , —OCF 3 , and —OCH 2 CF 3 ;

R 2 is selected from -aryl, -cycloalkyl, —CH 2 -aryl, —CH 2 -heteroaryl, —CH 2 -cycloalkyl, —CH 2 CH 2 -heterocyclyl, —S(O) 2 -aryl, —S(O) 2 -heteroaryl, —S(O) 2 -cycloalkyl, —S(O) 2 -heterocyclyl, —S(O) 2 —CH 2 CH 2 -heterocyclyl, —C(O)-cycloalkyl, —C(O)-aryl, —C(O)-heterocyclyl, —C(O)—CH 2 -aryl, —C(O)—CH 2 -heteroaryl, —C(O)—N(CH 3 ) 2 , —C(O)—[OCH 2 CH 2 ] 2-6 -OCH 3 , —C(O)CH 2 CN, —C(O)CH 2 CH 2 CH 3 , —C(O)CH 2 CH(CH 3 ) 2 , —CH 2 CH 2 CN, —CH 2 CH 2 S(O) 2 CH 3 , —CH 2 S(O) 2 CH 3 , —CH 2 CH 2 NHC(O)CH 3 , —CH 2 CH(OCH 3 )CF 3 , —CH 2 CH 2 CH 2 CF 3 , —CH 2 CH(OH)CF 3 , —CH(CH 2 F)CH 2 F, and —R 4 —C(R 5 )(R 6 )—R 7 , wherein:

R 4 is selected from —CH 2 —, —CH(CH 3 )—, —C(CH 3 ) 2 —, —C(O)— and —S(O) 2 —;

each of R 5 and R 6 is independently selected from fluoro, —CH 3 , and —CH 2 CH 3 , or R 5 and R 6 are taken together to form ═O;

R 7 is selected from hydrogen, fluoro, —CN, —CH 3 , —CH 2 OH, —CH 2 OCH 3 , —CF 2 H, —CFH 2 , —CF 3 , —CF 2 CH 3 , —CH 2 CH 3 , —OCH 3 , and —N(C 1 -C 3 alkyl) 2 , and

any aryl, heteroaryl, heterocyclyl or cycloalkyl portion of R 2 is optionally substituted with up to two substituents independently selected from bromo, chloro, fluoro, —CN, —CH 3 , —CF 3 , —C(O)CH 3 , and morpholin-4-ylmethyl;

each R 3 , when present, is independently selected from ═O and fluoro;

n is 0, 1, 2, 3, or 4, wherein:

when n is 0, R 1 is —CH 3 , —CH 2 CH 3 , —OCH 3 , or —OCHF 2 , R 5 is fluoro, and R 6 is fluoro, then R 7 is other than fluoro;

when n is 0, R 1 is —CH 3 , —CH 2 CH 3 , —OCH 3 , or —OCHF 2 , R 5 is —CH 3 , and R 6 is —CH 3 , then R 7 is other than hydrogen; and

the compound is other than:

 or a substantially pure enantiomer thereof or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 having structural formula Ia:

or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 and n are as defined as in claim 1 .

3. The compound of claim 1 having structural formula Ib:

or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 and n are as defined as in claim 1 .

4. The compound of claim 3 , wherein R 1 is selected from —OCH 3 , chloro, methyl, —OCHF 2 , —NH(CH 3 ), —CH 2 CH 3 , —CH 2 CH 2 CH 3 , and —OCH 2 CF 3 .

5. The compound of claim 4 , wherein R 1 is selected from chloro, —OCH 3 and —OCHF 2 .

6. The compound of claim 5 , wherein R 2 is selected from —(CH 2 ) 3 CF 3 , —CH 2 CH(OH)CF 3 , —CH 2 CH(OCH 3 )CF 3 , —CH 2 CF 2 H, —CH 2 CF 2 CH 3 , —CH 2 CF 2 CH 2 CH 3 , —CH 2 CF 2 CF 3 , —CH 2 CF 2 CF 2 H, —CH 2 C(O)N(CH 2 CH 3 ) 2 , —CH 2 C(O)CH 3 , —CH 2 C(CH 3 ) 2 OCH 3 , —CH 2 C(CH 3 ) 2 F, —CH 2 C(CH 3 ) 2 CF 3 , —CH(CFH 2 ) 2 , —C(O)N(CH 3 ) 2 , —C(O)C(CH 3 ) 3 , —C(O)C(CH 3 ) 2 CF 3 , —C(O)—[OCH 2 CH 2 ] 6 CH 3 , —C(O)—[OCH 2 CH 2 ] 2 CH 3 , —C(CH 3 ) 2 C(O)CH 3 , —C(O)C(CH 3 ) 2 CH 2 CH 3 , —C(O)C(CH 3 ) 2 OCH 3 , —C(O)C(O)CH 3 , —C(O)CF 2 CH 2 OCH 3 , —C(O)CH(CH 3 )CH 2 CH 3 , —CH(CH 3 )CF 2 H, —CH 2 C(CH 3 ) 2 CN, —CH 2 CF 2 CH 2 OCH 3 , —CH 2 CF 2 CH 2 OH, —S(O) 2 C(CH 3 ) 3 , —CH 2 -cyclopropyl, —S(O) 2 -phenyl, —S(O) 2 -cyclopropyl, —C(O)-phenyl, —C(O)-cyclopropyl, 4-cyanophenylcarbonyl, benzylcarbonyl, 2-methyl-1H-imidazol-1-ylacetyl, 3-methylisoxazol-5 acetyl, 1-fluorocyclobutylcarbonyl, 1-methylcyclopentylcarbonyl, 1-methylcyclopropylcarbonyl, 2,2-difluorocyclopropylcarbonyl, 3,3-difluorocyclopentylcarbonyl, 4-methylcyclohexylcarbonyl, cyclobutylcarbonyl, cyclopentylcarbonyl, 1,3-dimehtylazetidin-3-ylcarbonyl, 1-methyl-4-fluoropiperidin-4-ylcarbonyl, 1-methylpiperidin-4-ylcarbonyl, 2,2-difluoropyrrolidin-1-ylcarbonyl, 3-methyloxetan-3-ylcarbonyl, 4,4-difluoropiperidine-1-ylcarbonyl, tetrahydrofuran-3-ylcarbonyl, tetrahydropyran-4-ylcarbonyl, 3-fluorobenzyl, 4-cyanobenzyl, 1-methyl-1H-pyrazol-2-ylmethyl, 1-methyl-1H-pyrazol-3-ylmethyl, 1-methyl-1H-pyrazol-4-ylmethyl, 2,6-dimethylpyridin-4-ylmethyl, 2-cyanopyridin-4-ylmethyl, 2-methylpyridin-4-ylmethyl, 2-trifluoromethylpyridin-4-ylmethyl, 3-fluoropyridin-4-ylmethyl, 4-cyanopyridin-3-ylmethyl, 5-cyanopyridin-2-ylmethyl, 5-fluoropyridin-3-ylmethyl, 6-methylpyridin-2-ylmethyl, 6-methylpyrimidin-4-ylmethyl, pyrazin-2-ylmethyl, pyridin-3-ylmethyl, pyridin-4-ylmethyl, pyridin-3-ylsulfonyl, pyrimidin-2-ylmethyl, pyrimidin-4-ylmethyl, pyrimidin-5-ylmethyl, cyclopropyl, azetidin-3-ylsulfonyl, morpholin-4-ylethylsulfonyl, morpholin-4-ylcarbonyl, pyrrolidin-1-ylethylsulfonyl, pyridin-2-ylmethyl, piperidin-4-ylsulfonyl, 4-methylpiperazin-1-ylcarbonyl, 4-fluorophenylsulfonyl, 4-fluorophenylmethyl, 4-fluorophenyl, 4-chlorophenyl, 4-(morpholin-1-ylmethyl)phenyl, 3,5-difluorophenylmethyl, 3-(morpholin-4-ylmethyl)phenyl, 2,6-difluorophenylmethyl, 1-trifluoromethylcycloprop-1-ylmethyl, 1-trifluoromethylcycloprop-1-ylcarbonyl, 1-trifluoromethylcyclobut-1-ylmethyl, 1-trifluoromethylcyclobut-1-ylcarbonyl, 1-methylpiperidin-4-ylsulfonyl, 1-methylazetidin-3-ylsulfonyl, 1-fluorocycloprop-1-ylmethyl, and 1-fluorocyclobut-1-ylmethyl.

7. The compound of claim 5 , wherein R 2 is selected from —(CH 2 ) 3 CF 3 , —CH 2 CH(OH)CF 3 , —CH 2 CH(OCH 3 )CF 3 , —CH 2 CF 2 H, —CH 2 CF 2 CH 3 , —CH 2 CF 2 CH 2 CH 3 , —CH 2 CF 2 CF 3 , —CH 2 CF 2 CF 2 H, —CH 2 C(O)N(CH 2 CH 3 ) 2 , —CH 2 C(O)CH 3 , —CH 2 C(CH 3 ) 2 OCH 3 , —CH 2 C(CH 3 ) 2 F, —CH 2 C(CH 3 ) 2 CF 3 , —CH(CFH 2 ) 2 , —C(O)N(CH 3 ) 2 , —C(O)C(CH 3 ) 3 , —C(O)C(CH 3 ) 2 CF 3 , —C(O)—[OCH 2 CH 2 ] 6 CH 3 , —C(O)—[OCH 2 CH 2 ] 2 CH 3 , —CH 2 -cyclopropyl, —S(O) 2 -phenyl, —S(O) 2 -cyclopropyl, —C(O)-phenyl, —C(O)-cyclopropyl, azetidin-3-ylsulfonyl, morpholin-4-ylethylsulfonyl, morpholin-4-ylcarbonyl, pyrrolidin-1-ylethylsulfonyl, pyridin-2-ylmethyl, piperidin-4-ylsulfonyl, 4-methylpiperazin-1-ylcarbonyl, 4-fluorophenylsulfonyl, 4-fluorophenylmethyl, 4-fluorophenyl, 4-chlorophenyl, 4-(morpholin-1-ylmethyl)phenyl, 3,5-difluorophenylmethyl, 3-(morpholin-4-ylmethyl)phenyl, 2,6-difluorophenylmethyl, 1-trifluoromethylcycloprop-1-ylmethyl, 1-trifluoromethylcycloprop-1-ylcarbonyl, 1-trifluoromethylcyclobut-1-ylmethyl, 1-trifluoromethylcyclobut-1-ylcarbonyl, 1-methylpiperidin-4-ylsulfonyl, 1-methylazetidin-3-ylsulfonyl, 1-fluorocycloprop-1-ylmethyl, and 1-fluorocyclobut-1-ylmethyl.

8. The compound of claim 5 , wherein

R 2 is selected from —CH 2 -aryl, —CH 2 -cycloalkyl, —C(O)-cycloalkyl, and —R 4 —C(R 5 )(R 6 )—R 7 , wherein:

R 4 is —CH 2 —;

each of R 5 and R 6 is independently selected from fluoro and —CH 3 ;

R 7 is selected from hydrogen, fluoro, —CH 3 , —CF 2 H, —CF 3 , and —CF 2 CH 3 , any aryl or cycloalkyl portion of R 2 is optionally substituted with up to two substituents independently selected from fluoro and —CF 3 ; and

n is 0.

9. The compound of claim 5 , wherein R 2 is selected from —CH 2 CF 2 CF 3 , —CH 2 CF 2 CH 3 , —CH 2 CF 2 CHF 2 , —CH 2 CHF 2 , —CH 2 CF 2 CH 2 CH 3 , —CH 2 CF(CH 3 ) 2 , —C(CH 3 ) 2 C(O)CH 3 , —C(O)C(CH 3 ) 2 CH 2 CH 3 , —C(O)C(CH 3 ) 2 OCH 3 , —C(O)CF 2 CH 2 OCH 3 , —C(O)CH 2 CH(CH 3 ) 2 , —CH(CH 3 )CF 2 H, —CH 2 C(CH 3 ) 2 OCH 3 , —CH 2 CF 2 CH 2 OCH 3 , —CH 2 CH 2 CN, —S(O) 2 C(CH 3 ) 3 , 2,6-dimethylpyridin-4-ylmethyl, 1-fluorocyclobutylcarbonyl, 2-cyanopyridin-4-ylmethyl, 2-methylpyridin-4-ylmethyl, 2-trifluoromethylpyridin-4-ylmethyl, 3-fluorobenzyl, 3-fluoropyridin-4-ylmethyl, 4-cyanobenzyl, 4-cyanopyridin-3-ylmethyl, 4-methylcyclohexylcarbonyl, 5-cyanopyridin-2-ylmethyl, 5-fluoropyridin-3-ylmethyl, 6-methylpyridin-2-ylmethyl, 6-methylpyrimidin-4-ylmethyl, benzylcarbonyl, cyclobutylcarbonyl, cyclopropyl, pyrazin-2-ylmethyl, pyrimidin-4-ylmethyl 1-trifluoromethylcyclopropylmethyl, 1-trifluoromethylcyclobutylcarbonyl, 3,5-difluorophenylmethyl, 1-fluorocyclobutylmethyl, and 1-fluorocyclopropylmethyl.

10. The compound of claim 5 , wherein R 2 is selected from —CH 2 CF 2 CF 3 , —CH 2 CF 2 CH 3 , —CH 2 CF 2 CHF 2 , —CH 2 CHF 2 , —CH 2 CF 2 CH 2 CH 3 , —CH 2 CF(CH 3 ) 2 , 1-trifluoromethylcyclopropylmethyl, 1-trifluoromethylcyclobutylcarbonyl, 3,5-difluorophenylmethyl, 1-fluorocyclobutylmethyl, and 1-fluorocyclopropylmethyl.

11. A compound having structural formula II:

or a substantially pure enantiomer thereof, or a pharmaceutically acceptable salt of either of the foregoing, wherein:

R 11 is selected from Cl, —CH 3 , —CH 2 CH 3 , —CH 2 CH 2 CH 3 , —NH(CH 3 ), —OCH 3 , —OCHF 2 , —OCF 3 , and —OCH 2 CF 3 ;

R 12 is selected from optionally substituted pyridin-3-yl; optionally substituted pyrimidin-4-yl; optionally substituted pyrazin-2-yl; pyridin-2-yl substituted with one or more substituents independently selected from halo, methyl and morpholin-4-ylmethyl; pyrimidin-2-yl substituted with one or more substituents independently selected from halo, methyl and morpholin-4-ylmethyl; oxetan-3-yl substituted with one or more fluoro; and azetidin-3-yl substituted with acetyl;

each R 13 , when present, is independently selected from ═O and fluoro; and

m is 0, 1, 2, 3, or 4.

12. The compound of claim 11 having structural formula IIa:

or a pharmaceutically acceptable salt thereof, wherein R 11 , R 12 , R 13 and m are as defined as in claim 1 .

13. The compound of claim 11 having structural formula IIb:

or a pharmaceutically acceptable salt thereof, wherein R 11 , R 12 , R 13 and m are as defined as in claim 1 .

14. The compound of claim 13 , wherein R 11 is selected from chloro, —OCH 3 , —NH(CH 3 ), and —CH 3 .

15. The compound of claim 14 , wherein R 12 is selected from 5-chloropyrimindin-2-yl, 5-fluoropyrimidin-2-yl, pyridin-3-yl, pyrazin-2-yl, 6-methylpyridin-3-yl, 5-fluoropyridin-2-yl, 5-(morpholin-4-ylmethyl)pyridin-2-yl, pyrimidin-4-yl, 5-bromopyrimidin-2-yl, and 1-acetylazetidin-3-yl.

16. The compound of claim 14 , wherein R 12 is selected from 5-chloropyrimindin-2-yl, 5-fluoropyrimidin-2-yl, pyridin-3-yl, pyrazin-2-yl, 6-methylpyridin-3-yl, 5-fluoropyridin-2-yl, 5-(morpholin-4-ylmethyl)pyridin-2-yl, pyrimidin-4-yl, and 5-bromopyrimidin-2-yl.

17. A compound selected from any one of:

or a pharmaceutically acceptable salt thereof.

18. A composition comprising a compound of claim 1 ; and a pharmaceutically acceptable carrier.

19. A method of treating cancer in a patient comprising the step of administering to the patient in need thereof a compound according to claim 1 .

20. The compound of claim 1 , wherein R 4 is selected from —C(CH 3 ) 2 —, —C(O)— and —S(O) 2 —.

21. The compound of claim 1 , wherein R 2 is selected from -aryl, -cycloalkyl, —CH 2 -aryl, —CH 2 -heteroaryl, —CH 2 -cycloalkyl, —CH 2 CH 2 -heterocyclyl, —S(O) 2 -aryl, —S(O) 2 -heteroaryl, —S(O) 2 -cycloalkyl —S(O) 2 -heterocyclyl, —S(O) 2 —CH 2 CH 2 -heterocyclyl, —C(O)-cycloalkyl, —C(O)-aryl, —C(O)-heterocyclyl, —C(O)—CH 2 -aryl, —C(O)—CH 2 -heteroaryl, —C(O)—N(CH 3 ) 2 , —C(O)—[OCH 2 CH 2 ] 2-6 -OCH 3 , —C(O)CH 2 CN, —C(O)CH 2 CH 2 CH 3 , —C(O)CH 2 CH(CH 3 ) 2 , —CH 2 CH 2 CN, —CH 2 CH 2 S(O) 2 CH 3 , —CH 2 S(O) 2 CH 3 , —CH 2 CH 2 NHC(O)CH 3 , —CH 2 CH(OCH 3 )CF 3 , —CH 2 CH 2 CH 2 CF 3 , —CH 2 CH(OH)CF 3 , and —CH(CH 2 F)CH 2 F.